Lifeward Ltd. Ordinary Shares (LFWD) is a publicly traded Healthcare sector company. As of May 19, 2026, LFWD trades at $6.38 with a market cap of $18.62M and a P/E ratio of -0.36. LFWD moved -3.04% today. Year to date, LFWD is -12.06%; over the trailing twelve months it is -57.82%. Its 52-week range spans $4.14 to $48.00. Analyst consensus is buy with an average price target of $10.00. Rallies surfaces LFWD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in LFWD news today?
Lifeward Appoints 30-Year Veteran Dr. Rose as CMO to Advance ORMD-0801 Platform: Lifeward appointed Dr. Keith D. Rose, with 30 years of rehabilitation medicine and neuroscience expertise, as Chief Medical Officer to lead its global medical strategy and enhance clinical evidence generation across its neurorehabilitation and biomedical offerings. His promotion supports expansion of Lifeward’s Protein Oral Delivery biomed platform, including lead candidate ORMD-0801 targeting the diabetes market.
Lifeward Appoints 30-Year Veteran Dr. Rose as CMO to Advance ORMD-0801 Platform: Lifeward appointed Dr. Keith D. Rose, with 30 years of rehabilitation medicine and neuroscience expertise, as Chief Medical Officer to lead its global medical strategy and enhance clinical evidence generation across its neurorehabilitation and biomedical offerings. His promotion supports expansion of Lifeward’s Protein Oral Delivery biomed platform, including lead candidate ORMD-0801 targeting the diabetes market.
Does Rallies summarize LFWD news?
Yes. Rallies summarizes LFWD news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is LFWD research on Rallies investment advice?
No. Rallies provides research, data, and educational context for LFWD. It does not provide personalized investment advice.
